Drug Profile
Metronidazole/terconazole - Curatek Pharmaceuticals
Alternative Names: Terconazole/metronidazole-Curatek-PharmaceuticalsLatest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Curatek Pharmaceuticals
- Class Antibacterials; Antifungals; Antiprotozoals; Nitroimidazoles; Radiosensitisers; Small molecules
- Mechanism of Action Cell membrane permeability modulators; Cytochrome P 450 enzyme system inhibitors; DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Vaginitis
Most Recent Events
- 29 Sep 2021 Phase III development is ongoing in USA (Curatek Pharmaceuticals website, September 2021)
- 29 Sep 2021 Curatek Pharmaceuticals announces intention to submit NDA to US FDA for Vaginitis (Curatek Pharmaceuticals website, September 2021)
- 29 Sep 2021 Metronidazole/terconazole receives Qualified Infectious Disease Product (QIDP) status from the US FDA for Vaginitis (Curatek Pharmaceuticals website, September 2021)